Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $50
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $45 to $50.
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $45 to $50.